Can-Fite BioPharma Raises $175M for Liver Cancer & Psoriasis Drugs
Ticker: CANF · Form: 6-K · Filed: May 5, 2025 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | May 5, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: funding, clinical-trials, biotech
TL;DR
Can-Fite BioPharma secured $175M total funding, pushing Namodenoson (liver cancer) & Piclidenoson (psoriasis) into Phase 3 trials.
AI Summary
On May 5, 2025, Can-Fite BioPharma Ltd. announced it has raised a total of $175 million to date for the development of its drugs Namodenoson and Piclidenoson. These funds will support the advancement of these drugs into pivotal Phase 3 trials for liver cancer and psoriasis, respectively.
Why It Matters
This significant funding milestone allows Can-Fite BioPharma to progress its key drug candidates into late-stage clinical trials, potentially bringing new treatments for liver cancer and psoriasis closer to market.
Risk Assessment
Risk Level: medium — While the funding is substantial, the success of Phase 3 trials and subsequent regulatory approval remain significant hurdles for drug development.
Key Numbers
- $175M — Total Funding Raised (Funds development of Namodenoson and Piclidenoson into Phase 3 trials.)
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Issuer of the report and developer of the drugs
- $175 million (dollar_amount) — Total amount raised to date
- May 5, 2025 (date) — Date of the press release and filing
- Namodenoson (drug) — Drug candidate for liver cancer
- Piclidenoson (drug) — Drug candidate for psoriasis
FAQ
What is the total amount Can-Fite BioPharma has raised to date?
Can-Fite BioPharma has raised a total of $175 million to date.
What are the names of the drugs being developed with this funding?
The drugs being developed are Namodenoson and Piclidenoson.
What stage of clinical trials are Namodenoson and Piclidenoson entering?
Both drugs are advancing into pivotal Phase 3 trials.
For which medical conditions are Namodenoson and Piclidenoson intended?
Namodenoson is for liver cancer and Piclidenoson is for psoriasis.
On what date was this information announced?
The announcement was made on May 5, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 5, 2025 regarding Can-Fite BioPharma Ltd. (CANF).